MODELOS CLINICO-DOSIMETRICOS PREDICTIVOS DEL CONTROL BIOQUIMICO DEL CANCER DE PROSTATA ORGANO-CONFINADO TRATADO MEDIANTE

MODELOS CLINICO-DOSIMETRICOS
PREDICTIVOS DEL CONTROL BIOQUIMICO
DEL CANCER DE PROSTATA
ORGANO-CONFINADO TRATADO MEDIANTE
IMPLANTES RADIACTIVOS PERMANENTES
Alfredo Polo Rubio
Universidad de Barcelona
Departamento de Ciencias Clínicas
Año 2007

76:;:*907;<4
 6SZVU ;9 (+(4 ([SHZ KL HUH[VTxH O\THUH )HYJLSVUH! 4(::65  >PSSPHTZ 
>PSRPUZ,ZWH|H:(" 
2. Potenziani JC. Historia de la Urología (y II); 2006.
3. McNeal JE. Regional morphology and pathology of the prostate. Am J Clin Pathol
1968;49:347-357.
 >PSSPHTZ73>HY^PJR9.YH`(UH[VTxH)HYJLSVUH!:HS]H[" 
 (SILY[ZLU 7* -Y`IHJR +. :[VYLY ),, et al. 3VUN[LYT Z\Y]P]HS HTVUN TLU ^P[O
conservatively treated localized prostate cancer. Jama 1995;274:626-631.
 *OVKHR .> ;OPZ[LK 9( .LYILY .:, et al. Results of conservative management of
clinically localized prostate cancer. N Engl J Med 1994;330:242-248.
 4\YWO`41VOUZ[VU*>OLSHU7, et al. Changing trends in prostatic cancer. BJU Int
1999;83:786-791.
 0ZHHJZ>+L4HYaV(5LSZVU>.-VJ\ZVUWYVZ[H[LJHUJLYCancer Cell 2002;2:113-
116.
 :JHYKPUV7;>LH]LY9/\KZVU4(,HYS`KL[LJ[PVUVMWYVZ[H[LJHUJLYHum Pathol
1992;23:211-222.
10. Barrett-Connor E, Garland C, McPhillips JB, et al. A prospective, population-based
study of androstenedione, estrogens, and prostatic cancer. Cancer Res 1990;50:169-
173.
 2`WYPHUV\50ZHHJZ1;(J[P]H[PVUVMWYVNYHTTLKJLSSKLH[OPU[OLYH[]LU[YHSWYVZ[H[L
after castration. Endocrinology 1988;122:552-562.
12. Thompson IM, Goodman PJ, Tangen CM, et al. ;OL PUÅ\LUJL VM ÄUHZ[LYPKL VU [OL
development of prostate cancer. N Engl J Med 2003;349:215-224.
13. Ross R, Bernstein L, Judd H, et al.:LY\T[LZ[VZ[LYVULSL]LSZPUOLHS[O``V\UNISHJR
HUK^OP[LTLUJ Natl Cancer Inst 1986;76:45-48.
 9VZZ92)LYUZ[LPU33VIV9(, et al.HSWOHYLK\J[HZLHJ[P]P[`HUKYPZRVMWYVZ[H[L
JHUJLYHTVUN1HWHULZLHUK<:^OP[LHUKISHJRTHSLZLancet 1992;339:887-889.
15. Roach M, 3rd, Lu J, Pilepich MV, et al. Race and survival of men treated for prostate
cancer on radiation therapy oncology group phase III randomized trials. J Urol
2003;169:245-250.
16. Chuba PJ, Moughan J, Forman JD, et al. The 1989 patterns of care study for prostate
JHUJLY!Ä]L`LHYV\[JVTLZInt J Radiat Oncol Biol Phys 2001;50:325-334.
 4J5LHS1,)VZ[^PJR+.0U[YHK\J[HSK`ZWSHZPH!HWYLTHSPNUHU[SLZPVUVM[OLWYVZ[H[L
Hum Pathol 1986;17:64-71.
 ,WZ[LPU107V[[LY:9;OLWH[OVSVNPJHSPU[LYWYL[H[PVUHUKZPNUPÄJHUJLVMWYVZ[H[LULLKSL
IPVWZ`ÄUKPUNZ!PTWSPJH[PVUZHUKJ\YYLU[JVU[YV]LYZPLZJ Urol 2001;166:402-410.
19. Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: epidemiologic and
clinical features. J Urol 1993;150:797-802.
 /HU\Z4*AHNHYZ.27VSSHJR(-HTPSPHSWYVZ[H[LJHUJLY!V\[JVTLMVSSV^PUNYHKPH[PVU
[OLYHW` ^P[O VY ^P[OV\[ HKQ\]HU[ HUKYVNLU HISH[PVU Int J Radiat Oncol Biol Phys
1999;43:379-383.
 )V]H.:7HY[PU(>0ZHHJZ:+, et al. Biological aggressiveness of hereditary prostate
JHUJLY! SVUN[LYT L]HS\H[PVU MVSSV^PUN YHKPJHS WYVZ[H[LJ[VT` J Urol 1998;160:660-
663.
22. Gronberg H, Damber L, Tavelin B, et al. 5V KPMMLYLUJL PU Z\Y]P]HS IL[^LLU ZWVYHKPJ
familial and hereditary prostate cancer. Br J Urol 1998;82:564-567.
9,-,9,5*0(:
)0)306.9(-0*(:

 Modelos clínico-dosimetricos en braquiterapia prostática
76:;:*907;<4
 2\WLSPHU7(2SLPU,(>P[[L1:, et al. Familial prostate cancer: a different disease? J
Urol 1997;158:2197-2201.
 2\WLSPHU7(9LKK`*(9L\[OLY(4, et al. Aggressiveness of familial prostate cancer.
J Clin Oncol 2006;24:3445-3450.
 +LUUPZ 32 3`UJO *- ;VYULY 1* ,WPKLTPVSVNPJ HZZVJPH[PVU IL[^LLU WYVZ[H[P[PZ HUK
prostate cancer. Urology 2002;60:78-83.
 /H`LZ9)7V[[LYU34:[YPJRSLY/, et al.:L_\HSILOH]PV\Y:;+ZHUKYPZRZMVYWYVZ[H[L
cancer. Br J Cancer 2000;82:718-725.
 *HSSL,,9VKYPN\La*>HSRLY;O\YTVUK2, et al.6]LY^LPNO[VILZP[`HUKTVY[HSP[`MYVT
cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-
1638.
28. Calle EE, Teras LR, Thun MJ. Obesity and mortality. N Engl J Med 2005;353:2197-
2199.
29. Fincham SM, Hill GB, Hanson J, et al. Epidemiology of prostatic cancer: a case-control
study. Prostate 1990;17:189-206.
 /ZPUN(>4J3H\NOSPU12/Y\ILJA, et al. Tobacco use and prostate cancer: 26-year
MVSSV^\WVM<:]L[LYHUZAm J Epidemiol 1991;133:437-441.
 /ZPUN(>4J3H\NOSPU12:JO\THU34, et al. Diet, tobacco use, and fatal prostate
cancer: results from the Lutheran Brotherhood Cohort Study. Cancer Res 1990;50:6836-
6840.
32. Elghany NA, Schumacher MC, Slattery ML, et al. Occupation, cadmium exposure, and
prostate cancer. Epidemiology 1990;1:107-115.
 .SLHZVU + ;OL =L[LYHU»Z (KTPUPZ[YH[PVU *VVWLYH[P]L <YVSVNPJ 9LZLHYJO .YV\W!
histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, editor.
Urologic Pathology: The Prostate. Philadelphia: Lea and Febiger; 1977. pp. 171-198.
34. Ruijter E, van Leenders G, Miller G, et al. Errors in histological grading by prostatic
needle biopsy specimens: frequency and predisposing factors. J Pathol 2000;192:229-
233.
 (SSZIYVVR >* 1Y 4HUNVSK 2( 1VOUZVU 4/, et al. Interobserver reproducibility of
Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol 2001;32:74-
80.
 .LYILY.:*OVKHR .> +PNP[HS YLJ[HSL_HTPUH[PVUPU[OLLHYS` KL[LJ[PVU VMWYVZ[H[L
cancer. Urol Clin North Am 1990;17:739-744.
 7HY[PU(>@VV1*HY[LY/), et al.;OL\ZLVMWYVZ[H[LZWLJPÄJHU[PNLUJSPUPJHSZ[HNL
HUK.SLHZVUZJVYL[VWYLKPJ[WH[OVSVNPJHSZ[HNLPUTLU^P[OSVJHSPaLKWYVZ[H[LJHUJLY
J Urol 1993;150:110-114.
38. Carvalhal GF, Smith DS, Mager DE, et al. Digital rectal examination for detecting prostate
JHUJLY H[ WYVZ[H[L ZWLJPÄJ HU[PNLU SL]LSZ VM  UNTS VY SLZZ J Urol 1999;161:835-
839.
39. Schroder FH, van der Maas P, Beemsterboer P, et al. Evaluation of the digital rectal
examination as a screening test for prostate cancer. Rotterdam section of the European
Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 1998;90:1817-
1823.
 )YH^LY42*OL[ULY47)LH[PL1, et al.:JYLLUPUNMVYWYVZ[H[PJJHYJPUVTH^P[OWYVZ[H[L
ZWLJPÄJHU[PNLUJ Urol 1992;147:841-845.
 (YTIY\Z[LY+(7YVZ[H[LZWLJPÄJHU[PNLU!IPVJOLTPZ[Y`HUHS`[PJHSTL[OVKZHUKJSPUPJHS
application. Clin Chem 1993;39:181-195.
 -PSLSSH ? 4VSPUH 9 )HSSLZ[H (4, et al. =HS\L VM 7:( WYVZ[H[LZWLJPÄJ HU[PNLU PU
[OL KL[LJ[PVU VM WYVZ[H[L JHUJLY PU WH[PLU[Z ^P[O \YVSVNPJHS Z`TW[VTZ 9LZ\S[Z VM H
multicentre study. Eur J Cancer 1996;32A:1125-1128.
43. Zlotta AR, Djavan B, Marberger M, et al.7YVZ[H[LZWLJPÄJHU[PNLUKLUZP[`VM[OL[YHUZP[PVU
aVUL!HUL^LMMLJ[P]LWHYHTL[LYMVYWYVZ[H[LJHUJLYWYLKPJ[PVUJ Urol 1997;157:1315-
1321.
 :VIPU3/>P[[LRPUK*;54*SHZZPÄJH[PVUVMTHSPNUHU[[\TV\YZ[OLK!>PSSL`3PZZ"
1997.
 9PMRPU4+ALYOV\UP,(.H[ZVUPZ*(, et al. Comparison of magnetic resonance imaging

POSTSCRIPTUM 
76:;:*907;<4
and ultrasonography in staging early prostate cancer. Results of a multi-institutional
cooperative trial. N Engl J Med 1990;323:621-626.
 +»(TPJV (= :JOUHSS 4 >OP[[PUN[VU 9, et al. Endorectal coil magnetic resonance
PTHNPUN PKLU[PÄLZ SVJHSS` HK]HUJLK WYVZ[H[L JHUJLY PU ZLSLJ[ WH[PLU[Z ^P[O JSPUPJHSS`
localized disease. Urology 1998;51:449-454.
 *OLUN.**OLU4/>OP[[PUN[VU9, et al. Clinical utility of endorectal MRI in determining
7:( V\[JVTL MVY WH[PLU[Z ^P[O IPVWZ` .SLHZVU ZJVYL  7:( #VY$ HUK JSPUPJHSS`
localized prostate cancer. Int J Radiat Oncol Biol Phys 2003;55:64-70.
 3L]YHUA.VUaHSLa1(+PVRUV(*, et al. Are pelvic computed tomography, bone scan
and pelvic lymphadenectomy necessary in the staging of prostatic cancer? Br J Urol
1995;75:778-781.
  *O`IV^ZRP -4 2LSSLY 11 )LYNZ[YHSO ,1, et al. Predicting radionuclide bone scan
ÄUKPUNZPUWH[PLU[Z^P[OUL^S`KPHNUVZLK\U[YLH[LKWYVZ[H[LJHUJLY!WYVZ[H[LZWLJPÄJ
antigen is superior to all other clinical parameters. J Urol 1991;145:313-318.
 3LL 5 -H^HHa 9 6SZZVU *(, et al. >OPJO WH[PLU[Z ^P[O UL^S` KPHNUVZLK WYVZ[H[L
cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat
Oncol Biol Phys 2000;48:1443-1446.
51. de Jong IJ, Pruim J, Elsinga PH, et al. 11C-choline positron emission tomography for
the evaluation after treatment of localized prostate cancer. Eur Urol 2003;44:32-38;
discussion 38-39.
52. de Jong IJ, Pruim J, Elsinga PH, et al.=PZ\HSPaH[PVUVMWYVZ[H[LJHUJLY^P[O*JOVSPUL
positron emission tomography. Eur Urol 2002;42:18-23.
53. Picchio M, Landoni C, Messa C, et al.7VZP[P]LB*DJOVSPULHUKULNH[P]LB-D-+.^P[O
positron emission tomography in recurrence of prostate cancer. AJR Am J Roentgenol
2002;179:482-484.
54. Picchio M, Messa C, Landoni C, et al. Value of [11C]choline-positron emission
[VTVNYHWO`MVYYLZ[HNPUNWYVZ[H[LJHUJLY!HJVTWHYPZVU^P[OB-DÅ\VYVKLV_`NS\JVZL
positron emission tomography. J Urol 2003;169:1337-1340.
 )\IVSa; >HZZVU1/ 3\@HV ., et al. Treatments for prostate cancer in older men:
1984-1997. Urology 2001;58:977-982.
56. Gerber GS, Thisted RA, Scardino PT, et al.9LZ\S[ZVMYHKPJHSWYVZ[H[LJ[VT`PUTLU^P[O
clinically localized prostate cancer. Jama 1996;276:615-619.
 /HU47HY[PU(>7V\UK*9, et al. Long-term biochemical disease-free and cancer-
ZWLJPÄJ Z\Y]P]HS MVSSV^PUN HUH[VTPJ YHKPJHS YL[YVW\IPJ WYVZ[H[LJ[VT` ;OL `LHY
1VOUZ/VWRPUZL_WLYPLUJLUrol Clin North Am 2001;28:555-565.
 /\SS.>9HIIHUP-(IIHZ-, et al.*HUJLYJVU[YVS^P[OYHKPJHSWYVZ[H[LJ[VT`HSVULPU
1,000 consecutive patients. J Urol 2002;167:528-534.
  APUJRL / 6LZ[LYSPUN 1, )S\[L 43, et al. Long-term (15 years) results after radical
WYVZ[H[LJ[VT` MVY JSPUPJHSS` SVJHSPaLK Z[HNL ;J VY SV^LY WYVZ[H[L JHUJLY J Urol
1994;152:1850-1857.
 *H[HSVUH>1:TP[O+:*HUJLY YLJ\YYLUJLHUKZ\Y]P]HSYH[LZHM[LYHUH[VTPJYHKPJHS
retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol
1998;160:2428-2434.
 ,HZ[OHT1(:JHYKPUV7;9HKPJHSWYVZ[L[LJ[VT`0U!>HSZO7*.P[[LZ9-7LYST\[[LY
AD, et al.LKP[VYZ*HTWILSS»Z<YVSVN`7OPSHKLSWOPH!>):H\UKLYZ*VTWHU`" 
 -V^SLY-11Y)HYY`413\@HV., et al.7H[PLU[YLWVY[LKJVTWSPJH[PVUZHUKMVSSV^\W
treatment after radical prostatectomy. The National Medicare Experience: 1988-1990
(updated June 1993). Urology 1993;42:622-629.
 >HSZO 7* 7H[PLU[YLWVY[LK \YPUHY` JVU[PULUJL HUK ZL_\HS M\UJ[PVU HM[LY HUH[VTPJ
radical prostatectomy. J Urol 2000;164:242.
 >HSZO7*4HYZJORL79PJRLY+, et al. Patient-reported urinary continence and sexual
function after anatomic radical prostatectomy. Urology 2000;55:58-61.
 9HIIHUP-:[HWSL[VU(42H[[HU4>, et al. Factors predicting recovery of erections
after radical prostatectomy. J Urol 2000;164:1929-1934.
66. Quinlan DM, Epstein JI, Carter BS, et al.:L_\HSM\UJ[PVUMVSSV^PUNYHKPJHSWYVZ[H[LJ[VT`!
PUÅ\LUJLVMWYLZLY]H[PVUVMUL\YV]HZJ\SHYI\UKSLZJ Urol 1991;145:998-1002.

 Modelos clínico-dosimetricos en braquiterapia prostática
76:;:*907;<4
 *H[HSVUH >1 *HY]HSOHS .- 4HNLY +,, et al. Potency, continence and complication
rates in 1,870 consecutive radical retropubic prostatectomies. J Urol 1999;162:433-
438.
 *VUZLUZ\ZZ[H[LTLU[!N\PKLSPULZMVY7:(MVSSV^PUNYHKPH[PVU[OLYHW`(TLYPJHU:VJPL[`
for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys
1997;37:1035-1041.
  /VY^P[a,4=PJPUP-(APHQH,3, et al.;OLJVYYLSH[PVUIL[^LLU[OL(:;96*VUZLUZ\Z
7HULSKLÄUP[PVUVMIPVJOLTPJHSMHPS\YLHUKJSPUPJHSV\[JVTLMVYWH[PLU[Z^P[OWYVZ[H[L
JHUJLY [YLH[LK ^P[O L_[LYUHS ILHT PYYHKPH[PVU (TLYPJHU :VJPL[` VM ;OLYHWL\[PJ
Radiology and Oncology. Int J Radiat Oncol Biol Phys 1998;41:267-272.
 /HUSVU(3/HURZ.,:JY\[PU`VM[OL(:;96JVUZLUZ\ZKLÄUP[PVUVMIPVJOLTPJHSMHPS\YL
in irradiated prostate cancer patients demonstrates its usefulness and robustness.
American Society for Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys
2000;46:559-566.
 3H^[VU*(+LZPS]PV43LL>9, et al. Results of a phase II trial of transrectal ultrasound-
N\PKLKWLYTHULU[YHKPVHJ[P]LPTWSHU[H[PVUVM[OLWYVZ[H[LMVYKLÄUP[P]LTHUHNLTLU[VM
localized adenocarcinoma of the prostate (Radiation Therapy Oncology Group 98-05).
Int J Radiat Oncol Biol Phys 2007;67:39-47.
 9VHJO 4 YK /HURZ . ;OHTLZ / 1Y, et al. +LÄUPUN IPVJOLTPJHS MHPS\YL MVSSV^PUN
YHKPV[OLYHW`^P[OVY^P[OV\[OVYTVUHS[OLYHW`PUTLU^P[OJSPUPJHSS`SVJHSPaLKWYVZ[H[L
cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J
Radiat Oncol Biol Phys 2006;65:965-974.
 7LYLa*(/HURZ.,3LPILS:(, et al. Localized carcinoma of the prostate (stages T1B,
;*;HUK;9L]PL^VMTHUHNLTLU[^P[OL_[LYUHSILHTYHKPH[PVU[OLYHW`Cancer
1993;72:3156-3173.
 .YLJV*ALSLMZR`419HKPVOLYHW`MVYWYVZ[H[LJHUJLY(TZ[LYKHT!/HY^VVK(JHKLTPJ
Publishers; 2000.
 )HNZOH^ 4( 2HWSHU 0+ *V_ 9* 7YVZ[H[L JHUJLY 9HKPH[PVU [OLYHW` MVY SVJHSPaLK
disease. Cancer 1993;71:939-952.
 APL[THU(3*VLU11+HSSV^2*, et al. The treatment of prostate cancer by conventional
radiation therapy: an analysis of long-term outcome. Int J Radiat Oncol Biol Phys
1995;32:287-292.
 2\IHU+(LS4HOKP(4:JOLSSOHTTLY7-7YVZ[H[LZWLJPÄJHU[PNLUMVYWYL[YLH[TLU[
WYLKPJ[PVU HUK WVZ[[YLH[TLU[ L]HS\H[PVU VM V\[JVTL HM[LY KLÄUP[P]L PYYHKPH[PVU MVY
prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:307-316.
 /HURZ.,/HUSVU (3 ,WZ[LPU), et al. +VZL YLZWVUZLPUWYVZ[H[LJHUJLY^P[O
`LHYZ»MVSSV^\WInt J Radiat Oncol Biol Phys 2002;54:427-435.
  7VSSHJR(/HUSVU(3/VY^P[a,4, et al. Prostate cancer radiotherapy dose response:
an update of the fox chase experience. J Urol 2004;171:1132-1136.
 7VSSHJR(AHNHYZ.2:TP[O3., et al. Preliminary results of a randomized radiotherapy
KVZLLZJHSH[PVUZ[\K`JVTWHYPUN.`^P[O.`MVYWYVZ[H[LJHUJLYJ Clin Oncol
2000;18:3904-3911.
 7VSSHJR(AHNHYZ.2:[HYRZJOHSS., et al. Prostate cancer radiation dose response:
results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys
2002;53:1097-1105.
 ALSLMZR` 41 3LPILS :( .H\KPU 7), et al. +VZL LZJHSH[PVU ^P[O [OYLLKPTLUZPVUHS
conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol
Biol Phys 1998;41:491-500.
 ALSLMZR`41-\RZA/\U[4, et al. High dose radiation delivered by intensity modulated
conformal radiotherapy improves the outcome of localized prostate cancer. J Urol
2001;166:876-881.
 ALSLMZR`41-\RZA/\U[4, et al. High-dose intensity modulated radiation therapy for
prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat
Oncol Biol Phys 2002;53:1111-1116.
 2\WLSPHU7(4VOHU+:3`VUZ1, et al. Higher than standard radiation doses (> or =72
.`^P[OVY^P[OV\[HUKYVNLUKLWYP]H[PVUPU[OL[YLH[TLU[VMSVJHSPaLKWYVZ[H[LJHUJLY